Though safe, nilotinib does not show promise for benefit for Parkinson’s disease

CHICAGO (December 5, 2019) — Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson’s Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson’s drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced…

‘Virtual biopsy’ allows doctors to accurately diagnose precancerous pancreatic cysts

Research from doctors at The Ohio State University Wexner Medical Center finds a new “virtual biopsy” allows them to definitively diagnose cysts in the pancreas with unprecedented accuracy. This means they can eliminate precancerous cysts and potentially save lives. The current standard involves testing the fluid inside the cysts. It correctly identifies them as benign…

Next generation of CAR-T cells possible

A new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human cancer cells grown in the laboratory and in mice, according to a study by researchers at the Stanford University School of Medicine. The ability to circumvent the exhaustion that the genetically engineered cells often…